TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16500638

Group type: EXPERIMENTAL
Intervention: Visual cue of snake (threatening stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual cue of flower or mushroom (non-threatening stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported fear of snakes and spiders
Number of subjects: 0
Study: 15618322

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 8

Group type: COMPARATOR
Intervention: Early follicular phase
Number of subjects: 8

Group type: COMPARATOR
Intervention: Midluteal phase
Number of subjects: 8
Study: 12097224

Group type: EXPERIMENTAL
Intervention: External inhibition of learned rules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased stimulus salience
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 10980854

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study: 7481864

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus doxorubicin plus escalating doses of paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus doxorubicin plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin with or without ifosfamide or dibromodulcitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin with ifosfamide or dibromodulcitol plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel given concomitantly with radiation
Number of subjects: 0
Study: 2127008

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2
Study: 6290980

Group type: EXPERIMENTAL
Intervention: pirprofen 200 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: pirprofen 400 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: ketoprofen 150 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study: 31832778

Group type: EXPERIMENTAL
Intervention: Intravenous triglyceride (TG) infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 21
Study: 28601268

Group type: EXPERIMENTAL
Intervention: Crotalidae polyvalent immune Fab (ovine) (FabAV) antivenom
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26733110

Group type: EXPERIMENTAL
Intervention: Tocilizumab added to methotrexate (add-on)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Tocilizumab switched from methotrexate (switch)
Number of subjects: 223
Study: 24691771

Group type: EXPERIMENTAL
Intervention: Group-based exercise program (twice a week for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual life activities (control group)
Number of subjects: 48
Study: 23168226

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted turbinoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diode laser assisted turbinoplasty
Number of subjects: 40
Study: 19417225

Group type: EXPERIMENTAL
Intervention: Uncoupled crank system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional crank system
Number of subjects: 14
Study: 17650794

Group type: EXPERIMENTAL
Intervention: Combined therapy of prednisone and cyclophosphamide (CTX) plus Chinese medicine Langchuang Recipe after gamma‐globulin treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prednisone and CTX
Number of subjects: 19
Study: 16270522

Group type: EXPERIMENTAL
Intervention: FAC (5‐fluorouracil, Doxorubicin, Cyclophosphamide)
Number of subjects: 688

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5‐fluorouracil)
Number of subjects: 688
Study: 12037371

Group type: EXPERIMENTAL
Intervention: 6 mmol/l sodium hexafluorosilicate‐calcium chloride‐based two‐solution fluoride rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 mmol/l sodium fluoride rinse
Number of subjects: 0
Study: 10221723

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 41
Study: 7608262

Group type: EXPERIMENTAL
Intervention: Naltrexone (Nal; 100 mg/day) during estradiol (E2) and progesterone (P) administration (Nal 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Naltrexone (Nal; 100 mg/day) during pulsatile GnRH administration (Nal 2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pulsatile GnRH administration (10 micrograms/pulse, iv, every 90 min)
Number of subjects: 9
Study: 2404488

Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5% MK-927
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 714260

Group type: EXPERIMENTAL
Intervention: Prednisolone with or without azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0
Study: 31266608

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study: 29426436

Group type: EXPERIMENTAL
Intervention: Topical silicone gel (Dermatix Ultra) applied to one scar for 2 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo applied to the other scar for 2 months
Number of subjects: 12
Study: 26945393

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (1-2 post-tetanic count, n=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (1-2 train-of-four response, n=36)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 72
Study: 24508983

Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation program
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Reactive telephone counseling
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Self-help booklet
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Control group (Reactive telephone counseling)
Number of subjects: 1809
Study: 23232151

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20666748

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cold lateral condensation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 86

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 86
Study: 17404119

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Collaborative care
Number of subjects: 293
Study: 16109116

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/d
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study: 12099124

Group type: EXPERIMENTAL
Intervention: Distance learning module
Number of subjects: 53

Group type: COMPARATOR
Intervention: Preventive care guideline (Control)
Number of subjects: 53
Study: 10405234

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg every 8 hours for 24 hours)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg every 8 hours for 24 hours)
Number of subjects: 36
Study: 7575799

Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: APACHE II scoring system
Number of subjects: 28
Study: 2180390

Group type: EXPERIMENTAL
Intervention: Cephalothin 2 g X 4 on the day of operation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Methicillin 1 g X 4 on the day of operation
Number of subjects: 174
Study: 7361966

Group type: EXPERIMENTAL
Intervention: Mailed immunization reminder to parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mailed reminder (control group)
Number of subjects: 0
Study: 31701610

Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT)
Number of subjects: 257
Study: 27329448

Group type: EXPERIMENTAL
Intervention: Darapladib (selective Lp-PLA2 inhibitor)
Number of subjects: 14500

Group type: EXPERIMENTAL
Intervention: High Lp-PLA2 activity (baseline measurement)
Number of subjects: 14500
Study: 24995472

Group type: EXPERIMENTAL
Intervention: Silicone impressions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alginate impressions
Number of subjects: 0
Study: 22904178

Group type: EXPERIMENTAL
Intervention: Cholecalciferol/calcium
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cholecalciferol/placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Calcium/placebo
Number of subjects: 173
Study: 20053788

Group type: EXPERIMENTAL
Intervention: Ariva/Stonewall (smokeless tobacco lozenges)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 31
Study: 18046523

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 5344
Study: 15817428

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg loading dose followed by 0.18 mg/kg/h continuous infusion for 6 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CVVH (Continuous Veno-Venous Hemofiltration)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No CVVH
Number of subjects: 24
Study: 14569215

Group type: EXPERIMENTAL
Intervention: PulStar Function Recording and Analysis System (PulStarFRAS)
Number of subjects: 18
Study: 10906641

Group type: EXPERIMENTAL
Intervention: Sunscreen alone (gel)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sunscreen alone (cream)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insect repellent alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insect repellent applied before sunscreen (group 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insect repellent applied before sunscreen (group 2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insect repellent applied after sunscreen (group 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insect repellent applied after sunscreen (group 2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no sunscreen or insect repellent)
Number of subjects: 8
Study: 8814740

Group type: EXPERIMENTAL
Intervention: Helium ion therapy
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: 125I radioactive plaque therapy
Number of subjects: 426

Group type: COMPARATOR
Intervention: Helium ion therapy and 125I brachytherapy
Number of subjects: 426
Study: 1705488

Group type: EXPERIMENTAL
Intervention: rG-CSF (2 micrograms/kg per day for 14 consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no rG-CSF)
Number of subjects: 0
Study: 6403413

Group type: COMPARATOR
Intervention: Hexamethylmelamine, Adriamycin, and cyclophosphamide (HAC)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Melphalan and cis-platinum
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Residual tumor diameter <2 cm
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Residual tumor diameter >2 cm
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Hematologic toxicity
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Gastrointestinal toxicity
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Other toxicities
Number of subjects: 169
Study: 31627889

Group type: EXPERIMENTAL
Intervention: Colloid group (HES solution 750 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Crystalloid group (LR solution 2825 ml)
Number of subjects: 80
Study: 29430176

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alpha 1 antitrypsin (AAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26444030

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 200
Study: 24740205

Group type: EXPERIMENTAL
Intervention: Dietary intake of citrus, green vegetables, red meat, shellfish, fish, peanuts, rice, butter, coffee, beer, liquor, total alcohol, and multivitamins
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Intraindividual metabolite variability
Number of subjects: 502
Study: 22176868

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: External beam pelvic radiotherapy (EBRT)
Number of subjects: 427
Study: 20964833

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulphasalazine and hydroxychloroquine (treatment A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infliximab (treatment B)
Number of subjects: 40
Study: 17347185

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg ml‐1
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ephedrine 4.5 mg ml‐1
Number of subjects: 54
Study: 16329017

Group type: EXPERIMENTAL
Intervention: Simulator training with the AccuTouch flexible endoscopy simulator
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 24
Study: 12077742

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet (73 mg/d isoflavone)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy diet (10 mg/d isoflavone)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-fat dairy food control phase
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy diet
Number of subjects: 41
Study: 9794350

Group type: EXPERIMENTAL
Intervention: Exercise training group (3 times a week, averaging 83% of maximum heart rate)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Contact control group (nonexercising, 3 supervised health education lectures per week)
Number of subjects: 109
Study: 8588499

Group type: EXPERIMENTAL
Intervention: Phase related external suction (PRES) method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional neck suction technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Noninvasive Finapres blood pressure device
Number of subjects: 10
Study: 2911850

Group type: EXPERIMENTAL
Intervention: Short-term doxorubicin infusion (10 mg/m2/day for 5 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long-term doxorubicin infusion (3 mg/m2/day for 5-104 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short-term doxorubicin infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long-term doxorubicin infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous infusion of doxorubicin
Number of subjects: 15
Study: 1100969

Group type: EXPERIMENTAL
Intervention: DADDS
Number of subjects: 50

Group type: COMPARATOR
Intervention: DDS
Number of subjects: 50
Study: 31424962

Group type: EXPERIMENTAL
Intervention: Herbal extracts (mangosteen, Lithospermum officinale, Tribulus terrestris L., Houttuynia cordata Thunb)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study: 31254717

Group type: EXPERIMENTAL
Intervention: Counterconditioning with positive film clips
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard extinction training
Number of subjects: 177

Group type: COMPARATOR
Intervention: Extinction training with non-contingent exposure to positive film clips
Number of subjects: 177
Study: 27489211

Group type: EXPERIMENTAL
Intervention: TV‐1106 (7.5, 15, 50, and 100 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: TV‐1106 (7.5 and 15 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: TV‐1106 (50 and 100 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: TV‐1106
Number of subjects: 88
Study: 26409167

Group type: EXPERIMENTAL
Intervention: Subsidised healthcare
Number of subjects: 2151

Group type: COMPARATOR
Intervention: Control group (no subsidised care)
Number of subjects: 2151
Study: 22610853

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17047181

Group type: EXPERIMENTAL
Intervention: Sutured securement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tape securement
Number of subjects: 66
Study: 14679674

Group type: EXPERIMENTAL
Intervention: Low-dose perindopril/indapamide (2 mg and 0.625 mg daily)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Sequential treatment of atenolol (50 mg) then losartan (50 mg) then amlodipine (5 mg)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Step-by-step strategy of valsartan (40 mg then 80 mg then 80 mg plus hydrochlorothiazide 12.5 mg)
Number of subjects: 533
Study: 10989766

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe daily)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe twice weekly)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Once weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe once weekly)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (no iron supplement)
Number of subjects: 520
Study: 8781867

Group type: EXPERIMENTAL
Intervention: Heavy weight training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 1534832

Group type: EXPERIMENTAL
Intervention: Long-term sodium restriction (daily sodium intake reduced to less than 70 mmol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long-term sodium restriction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no sodium restriction)
Number of subjects: 40
Study: 6691613

Group type: EXPERIMENTAL
Intervention: Modular course
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lecture course
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Refresher course after one year
Number of subjects: 104

Group type: COMPARATOR
Intervention: No refresher course
Number of subjects: 104
Study: 31782367

Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice (1.5 mL kg‐1)
Number of subjects: 89
Study: 30939143

Group type: EXPERIMENTAL
Intervention: Telephone-based patient-centered intervention delivered by a clinical pharmacist
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1400
Study: 28262269

Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 1108
Study: 26385340

Group type: EXPERIMENTAL
Intervention: Face-to-face individual MI
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Online group MI
Number of subjects: 495

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 495
Study: 23561008

Group type: EXPERIMENTAL
Intervention: Okoubaka aubrevillei (potency C12)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (sucrose globules)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Qualitative comparison of symptom profiles
Number of subjects: 31
Study: 21392615

Group type: EXPERIMENTAL
Intervention: VEGF/FGF plasmid (n = 33)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo plasmid (n = 19)
Number of subjects: 52
Study: 19479153

Group type: EXPERIMENTAL
Intervention: 1 ml of 0.25% bupivacaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8
Study: 17229221

Group type: EXPERIMENTAL
Intervention: Enteral nutritional therapy (EN group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-nutritional therapy (non-EN group)
Number of subjects: 40
Study: 15535487

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 5 minutes after rocuronium administration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 1% twitch height (T1) recovery
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 25% twitch height (T25) recovery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Spontaneous recovery group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pyridostigmine groups (T1 and T25)
Number of subjects: 51